京都大学 / 新制・課程博士 / 博士(医学) / 甲第25166号 / 医博第5052号 / 新制||医||1071(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 藤田 恭之, 教授 上野 英樹, 教授 河本 宏 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

Acute myeloid leukemia (AML) develops following oncogenic alterations to hematopoietic stem (HSC) and progenitor cells (HSPCs) in the bone marrow, resulting in dysregulated proliferation of immature myeloid progenitors that interferes with normal hematopoiesis. Understanding the mechanisms of HSPC protection against damage and excessive division, and how these pathways are altered during leukemic progression, is vital for establishing effective therapies. Here, we show that autophagy, a lysosomal degradation pathway, is increased in HSPCs using a novel imaging flow cytometry autophagy assay. Loss of hematopoietic autophagy following deletion of key gene Atg5 resulted in increased HSC proliferation, leading to HSC exhaustion and bone marrow failure. Although erythrocyte and lymphocyte populations were negatively impacted by autophagy loss, myeloid cells showing immature characteristics were expanded. Deletion of Atg5 in an AML model resulted in increased proliferation under metabolic stress, dependent on the glycolytic pathway, and aberrant upstream mTOR signaling. Moreover, modulation of Atg5 altered leukemic response to culture with stromal cells. Finally, primary AML cells displayed multiple markers of decreased autophagy. These data suggest a role for autophagy in preserving HSC function, partially through suppression of HSPC proliferation, and indicate that decreased autophagy may benefit AML cells. We postulate that modulation of autophagy could help maintain stem cell function, for example during transplantation, and aid AML therapy in a setting-specific manner.

Yau Wai Lok. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 195-205). / Abstracts in English and Chinese. / ACKNOWLEDGEMENTS --- p.i / ABBREVIATIONS --- p.ii / ABSTRACT --- p.vii / 撮要 --- p.x / PUBLICATIONS --- p.xii / TABLE OF CONTENTS --- p.xiii / Chapter CHAPTER 1: --- GENERAL INTRODUCTION / Chapter 1.1 --- Hematopoiesis & Leukemia --- p.1 / Chapter 1.1.1 --- An Overview on Hematopoiesis --- p.1 / Chapter 1.1.2 --- An Overview of Leukemia --- p.4 / Chapter 1.1.2.2 --- Classification and Epidemiology of Leukemia --- p.5 / Chapter 1.1.2.3 --- Conventional Approaches to Leukemia Therapy --- p.8 / Chapter 1.1.2.4 --- Novel Approaches to Leukemia Therapy --- p.9 / Chapter 1.1.2.4.1 --- Differentiation Therapy --- p.10 / Chapter 1.1.2.4.2 --- Induction of Apoptosis --- p.10 / Chapter 1.1.2.4.3 --- Natural Products as a Source of Anti-leukemia Drug --- p.11 / Chapter 1.2 --- Cytokinins --- p.12 / Chapter 1.2.1 --- Historical Development and Occurrence of Cytokinins --- p.12 / Chapter 1.2.2 --- Functions of Cytokinins and the Signal Transduction of Cytokinins in Plants --- p.13 / Chapter 1.2.3 --- Phytochemistry and Metabolism of Cytokinins --- p.15 / Chapter 1.2.3.1 --- Chemical Structures of Cytokinins --- p.15 / Chapter 1.2.3.2 --- Biosynthesis of Cytokinins in Plants --- p.19 / Chapter 1.2.3.3 --- Metabolisms of Cytokinins in Plants and Animals --- p.22 / Chapter 1.2.4 --- Biological and Pharmacological Activities of Cytokinins in Animals --- p.23 / Chapter 1.2.4.1 --- Anti-aging Effect --- p.24 / Chapter 1.2.4.2 --- Anti-thrombosis Effect and Inhibition of Blood Platelet Aggregation --- p.24 / Chapter 1.2.4.3 --- Anti-tumor Effect --- p.25 / Chapter 1.3 --- Aims and Scopes of This Investigation --- p.27 / Chapter CHAPTER 2: --- MATERIALS AND METHODS / Chapter 2.1 --- Materials --- p.29 / Chapter 2.1.1 --- Animals --- p.29 / Chapter 2.1.2 --- Cell Lines --- p.29 / Chapter 2.1.3 --- "Cell Culture Medium, Buffers and Other Reagents" --- p.32 / Chapter 2.1.4 --- Reagents and Buffers for Flow Cytometry --- p.37 / Chapter 2.1.5 --- Reagents for DNA Extraction --- p.41 / Chapter 2.1.6 --- Cellular DNA Fragmentation ELISA Kit --- p.42 / Chapter 2.1.7 --- Reagents for Total RNA Isolation --- p.44 / Chapter 2.1.8 --- Reagents and Buffers for Reverse Transcription-Polymerase Chain Reaction (RT-PCR) --- p.46 / Chapter 2.1.9 --- Reagents and Buffers for Gel Electrophoresis for Nucleic Acids --- p.50 / Chapter 2.1.10 --- Reagents for Measuring Caspase Activity --- p.51 / Chapter 2.2 --- Methods --- p.54 / Chapter 2.2.1 --- Culture of the Tumor Cell Lines --- p.54 / Chapter 2.2.2 --- "Isolation, Preparation and Culture of Murine Peritoneal Macrophages" --- p.55 / Chapter 2.2.3 --- Determination of Cell Proliferation by [ 3H]-TdR Incorporation Assay --- p.55 / Chapter 2.2.4 --- Cytotoxicity Measurement by LDH Release Assay --- p.56 / Chapter 2.2.5 --- Determination of Cell Viability --- p.57 / Chapter 2.2.6 --- Determination of Anti-leukemic Activity In Vivo --- p.58 / Chapter 2.2.7 --- Analysis of Cell Cycle Profile/DNA Content by Flow Cytometry --- p.59 / Chapter 2.2.8 --- Measurement of Apoptosis --- p.59 / Chapter 2.2.9 --- Assessment of differentiation-associated characteristics --- p.63 / Chapter 2.2.10 --- Gene Expression Study --- p.67 / Chapter 2.2.11 --- Measurement of Caspase Activity --- p.68 / Chapter 2.2.12 --- Statistical Analysis --- p.70 / Chapter CHAPTER 3: --- STUDIES ON THE ANTI-PROLIFERATIVE EFFECT OF CYTOKININS ON LEUKEMIA CELLS / Chapter 3.1 --- Introduction --- p.71 / Chapter 3.2 --- Results --- p.72 / Chapter 3.2.1 --- Effect of Various Cytokinins and Their Riboside Derivatives on the Proliferation of Murine Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro --- p.72 / Chapter 3.2.2 --- Cytotoxicity of Kinetin and Kinetin Riboside on the WEHI-3B JCS Cells In Vitro --- p.86 / Chapter 3.2.3 --- Effects of Kinetin and Kinetin Riboside on the Proliferation of Various Leukemia Cell Lines In Vitro --- p.90 / Chapter 3.2.4 --- Cytotoxicity of Kinetin and Kinetin Riboside on Non-tumor Cell Lines and Primary Myeloid Cells In Vitro --- p.103 / Chapter 3.2.5 --- Kinetic and Reversibility Studies of the Anti-proliferative Effect of Kinetin and Kinetin Riboside on the WEHI-3B JCS Cells In Vitro --- p.107 / Chapter 3.2.6 --- Effects of Kinetin and Kinetin Riboside on the Cell Cycle Profile of WEHI-3B JCS Cells In Vitro --- p.115 / Chapter 3.2.7 --- Expression of Cell Cycle Related Genes in Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells In Vitro --- p.118 / Chapter 3.2.8 --- Effects of Kinetin and Kinetin Riboside on the In Vivo Tumorigenicity of WEHI-3B JCS Cells --- p.123 / Chapter 3.2.9 --- In Vivo Anti-tumor Effect of Kinetin and Kinetin Riboside on WEHI-3B JCS Cells --- p.126 / Chapter 3.3 --- Discussion --- p.129 / Chapter CHAPTER 4: --- STUDIES ON THE APOPTOSIS-INDUCING EFFECT OF CYTOKININS / Chapter 4.1 --- Introduction --- p.134 / Chapter 4.2 --- Results --- p.136 / Chapter 4.2.1 --- Induction of DNA Fragmentation of Cytokinins in the Murine Myeloid Leukemia WEHI-3B JCS Cells In Vitro --- p.136 / Chapter 4.2.2 --- Mitochondrial Membrane Potential of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells In Vitro --- p.144 / Chapter 4.2.3 --- Caspase Activities of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells In Vitro --- p.147 / Chapter 4.2.4 --- Induction of Reactive Oxygen Species in Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells In Vitro --- p.154 / Chapter 4.2.5 --- Expression of Apoptosis Regulatory Genes in Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells In Vitro --- p.157 / Chapter 4.3 --- Discussion --- p.163 / Chapter CHAPTER 5: --- STUDIES ON THE DIFFERENTIATION-INDUCING EFFECT OF CYTOKININS / Chapter 5.1 --- Introduction --- p.168 / Chapter 5.2 --- Results --- p.170 / Chapter 5.2.1 --- Morphology of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells --- p.170 / Chapter 5.2.2 --- Cell Size and Granularity of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells --- p.175 / Chapter 5.2.3 --- Changes in Surface Antigen Expression of Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells --- p.178 / Chapter 5.2.4 --- Monocytic Serine Esterase Activity in Kinetin- and Kinetin Riboside-treated WEHI-3B JCS Cells --- p.185 / Chapter 5.3 --- Discussion --- p.188 / Chapter CHAPTER 6: --- CONCLUSIONS AND FUTURE PERSPECTIVES --- p.190 / REFERENCES --- p.195

Lui Oi Lan. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves [216]-240). / Abstracts in English and Chinese. / ACKNOWLEDGEMENTS --- p.i / ABBREVIATIONS --- p.ii / ABSTRACT --- p.vii / 撮要 --- p.x / PUBLICATIONS --- p.xiii / TABLE OF CONTENTS --- p.xiv / Chapter CHAPTER 1: --- GENERAL INTRODUCTION / Chapter 1.1 --- Hematopoiesis and Leukemia --- p.1 / Chapter 1.1.1 --- An Overview on Hematopoietic Development --- p.1 / Chapter 1.1.2 --- Leukemia --- p.8 / Chapter 1.1.2.1 --- General Diagnostic Tests for Leukemia --- p.9 / Chapter 1.1.2.2 --- Classification and Epidemiology of Leukemia --- p.10 / Chapter 1.1.2.3 --- Conventional Approaches to Leukemia Therapy --- p.17 / Chapter 1.1.2.4 --- Novel Approaches to Leukemia Therapy --- p.20 / Chapter 1.2 --- Conjugated Linoleic Acid --- p.23 / Chapter 1.2.1 --- Introduction: Historical Development and Occurrence of Conjugated Linoleic Acid --- p.23 / Chapter 1.2.2 --- Phytochemistry and Metabolism of Conjugated Linoleic Acid --- p.24 / Chapter 1.2.2.1 --- Chemical Structures of Conjugated Linoleic Acid Isomers --- p.24 / Chapter 1.2.2.2 --- Biosynthesis of Conjugated Linoleic Acid --- p.26 / Chapter 1.2.2.3 --- Metabolism of Conjugated Linoleic Acid --- p.30 / Chapter 1.2.2.4 --- Mode of Entry and Tissue Incorporation of Conjugated Linoleic Acid --- p.33 / Chapter 1.2.2.5 --- Toxicology of Conjugated Linoleic Acid --- p.33 / Chapter 1.2.3 --- Physiological Activities of Conjugated Linoleic Acid: Reported Health Benefits --- p.35 / Chapter 1.2.3.1 --- Anti-adipogenesis / Chapter 1.2.3.2 --- Anti-diabetogenesis --- p.36 / Chapter 1.2.3.3 --- Anti-atherosclerosis --- p.38 / Chapter 1.2.3.4 --- Anti-carcinogenesis --- p.39 / Chapter 1.2.3.5 --- Anti-tumor Activity --- p.40 / Chapter 1.2.3.6 --- Effects of Conjugated Linoleic Acid on Lipid Metabolism --- p.44 / Chapter 1.2.3.6.1 --- Actions on Phospholipids by Conjugated Linoleic Acid --- p.45 / Chapter 1.2.3.6.2 --- Conjugated Linoleic Acid as a Ligand for the PPAR System --- p.47 / Chapter 1.2.3.7 --- Immunomodulation --- p.47 / Chapter 1.3 --- Aims and Scopes of This Investigation --- p.50 / Chapter CHAPTER 2: --- MATERIALS AND METHODS / Chapter 2.1 --- Materials / Chapter 2.1.1 --- Animals --- p.52 / Chapter 2.1.2 --- Cell Lines --- p.52 / Chapter 2.1.3 --- "Cell Culture Medium, Buffers and Other Reagents" --- p.52 / Chapter 2.1.4 --- Reagents for 3H-Thymidine Incorporation Assay --- p.54 / Chapter 2.1.5 --- Reagents and Buffers for Flow Cytometry --- p.58 / Chapter 2.1.6 --- Reagents for DNA Extraction --- p.59 / Chapter 2.1.7 --- Cell Death Detection ELISAPLUS Kit --- p.63 / Chapter 2.1.8 --- Reagents for Measuring Caspase Activity --- p.65 / Chapter 2.1.9 --- Reagents for Total RNA Isolation --- p.66 / Chapter 2.1.10 --- Reagents and Buffers for RT-PCR --- p.69 / Chapter 2.1.11 --- Reagents and Buffers for Gel Electrophoresis of Nucleic Acids --- p.74 / Chapter 2.1.12 --- "Reagents, Buffers and Materials for Western Blot Analysis" --- p.75 / Chapter 2.2 --- Methods / Chapter 2.2.1 --- Culture of the Tumor Cell Lines --- p.80 / Chapter 2.2.2 --- "Isolation, Preparation and Culture of Mouse Peritoneal Macrophages" --- p.81 / Chapter 2.2.3 --- Determination of Cell Viability --- p.82 / Chapter 2.2.4 --- Determination of Cell Proliferation by [3H]-TdR Incorporation Assay --- p.83 / Chapter 2.2.5 --- In Vivo Tumorigenicity Study --- p.83 / Chapter 2.2.6 --- Analysis of Cell Cycle Profile / DNA Content by Flow Cytometry --- p.83 / Chapter 2.2.7 --- Measurement of Apoptosis --- p.84 / Chapter 2.2.8 --- Determination of the Mitochondrial Membrane Potential --- p.86 / Chapter 2.2.9 --- Measurement of Caspase Activity --- p.87 / Chapter 2.2.10 --- Study of Intracellular Accumulation of Reactive Oxygen Species (ROS) --- p.88 / Chapter 2.2.11 --- Study of the Scavenging Activity of Antioxidants --- p.88 / Chapter 2.2.12 --- Gene Expression Study --- p.89 / Chapter 2.2.13 --- Protein Expression Study --- p.92 / Chapter 2.2.14 --- Measurement of Cell Differentiation --- p.95 / Chapter 2.2.15 --- Statistical Analysis --- p.98 / Chapter CHAPTER 3: --- STUDIES ON THE ANTI-TUMOR ACTICITY OF CONJUGATED LINOLEIC ACID ON MYELOID LEUKEMIA CELLS / Chapter 3.1 --- Introduction / Chapter 3.2 --- Results --- p.99 / Chapter 3.2.1 --- Anti-proliferative Activity of CLA-mix and CLA Isomers on Various Myeloid Leukemia Cell Lines In Vitro --- p.101 / Chapter 3.2.2 --- Cytotoxic Effect of CLA-mix on the WEHI-3B JCS Cells In Vitro --- p.109 / Chapter 3.2.3 --- Cytotoxic Effect of CLA-mix on Primary Murine Myeloid Cells In Vitro --- p.111 / Chapter 3.2.4 --- Kinetic and Reversibility Studies of the Anti-proliferative Activity of CLA-mix on the WEHI-3B JCS Cells --- p.113 / Chapter 3.2.5 --- Effect of CLA-mix and its isomers on the Cell Cycle Profiles of the WEHI-3B JCS Cells In Vitro --- p.116 / Chapter 3.2.6 --- Effect of CLA-mix and its isomer on the Expression of Cell Cycle-regulatory Genes in the WEHI-3B JCS Cells --- p.123 / Chapter 3.2.7 --- Effect of CLA-mix and its isomer on the In V Tumorigenicity of the WEHI-3B JCS Cells ivo --- p.128 / Chapter 3.3 --- Discussion --- p.131 / Chapter CHAPTER 4: --- STUDIES ON THE APOPTOSIS-INDUCING ACTIVITY OF CONJUGATED LINOLEIC ACID ON MYELOID LEUKEMIA CELLS / Chapter 4.1 --- Introduction --- p.141 / Chapter 4.2 --- Results --- p.141 / Chapter 4.2.1 --- Induction of Apoptosis in Both Murine and Human Myeloid Leukemia Cells by CLA --- p.144 / Chapter 4.2.2 --- Effect of CLA and its Isomer on the Mitochondrial Membrane Potential of the WEHI-3B JCS Cells --- p.151 / Chapter 4.2.3 --- Effect of CLA-mix and its Isomer on the Expression of Apoptosis-regulatory Genes of the Bcl-2 Family in the WEHI-3B JCS Cells --- p.154 / Chapter 4.2.4 --- Effect of CLA-mix and its Isomer on the Expression of Apoptosis-regulatory Proteins in the WEHI-3B JCS Cells --- p.158 / Chapter 4.2.5 --- Effect of CLA-mix and its Isomer on the Induction of Caspase Activity in the WEHI-3B JCS Cells --- p.161 / Chapter 4.2.6 --- Effect of CLA-mix and its Isomer on the Induction of ROS in the WEHI-3B JCS Cells --- p.170 / Chapter 4.2.7 --- Effect of Antioxidants on the Induction of ROS by CLA-mix and its Isomer in the WEHI-3B JCS Cells --- p.173 / Chapter 4.2.8 --- Effect of Antioxidants on the Induction of Apoptosis by CLA-mix and its Isomer in the WEHI-3B JCS Cells --- p.176 / Chapter 4.2 --- Discussion / Chapter CHAPTER 5: --- STUDIES ON THE DIFFERENTIATION-INDUCING ACTIVITY OF CONJUGATED LINOLEIC ACID ON MYELOID LEUKEMIA CELLS / Chapter 5.1 --- Introduction --- p.187 / Chapter 5.2 --- Results --- p.190 / Chapter 5.2.1 --- Morphological Alterations in CLA-mix- and CLA isomer-treated WEHI-3B JCS Cells --- p.190 / Chapter 5.2.2 --- Effects of CLA-mix on the Cell Size and Granularity of WEHI-3B JCS Cells --- p.196 / Chapter 5.2.3 --- Studies of the Surface Phenotypic Changes in the CLA-mix-treated WEHI-3B JCS cells --- p.198 / Chapter 5.2.4 --- Studies on the Induction of Monocytic Serine Esterase (MSE) Activity in the CLA-mix-treated WEHI-3B JCS Cells --- p.200 / Chapter 5.2.5 --- Studies on the Induction of Endocytic Activity in the CLA-mix-treated WEHI-3B JCS Cells --- p.201 / Chapter 5.2.6 --- Studies on the Expression of the Differentiation-regulatory Cytokine Genes in the CLA-mix-treated WEHI-3B JCS Cells --- p.202 / Chapter 5.3 --- Discussion --- p.204 / Chapter CHAPTER 6: --- CONCLUSIONS AND FUTURE PERSPECTIVES REFERENCES --- p.208 / REFERENCES --- p.217

Chin, Chi Hou. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves [165]-178). / Abstracts in English and Chinese. / Abstract --- p.i / Abstract in Chinese (摘要） --- p.iv / Acknowledgements --- p.vi / Abbreviations --- p.vii / List of Figures and Tables --- p.xi / Publications --- p.xv / Chapter Chapter 1 --- General Introduction / Chapter 1.1. --- Hematopoiesis and Leukemia --- p.2 / Chapter 1.1.1. --- Hematopoiesis --- p.2 / Chapter 1.1.2. --- Leukemia --- p.8 / Chapter 1.1.2.1. --- Overview of leukemia --- p.8 / Chapter 1.1.2.2. --- Symptoms and diagnosis of leukemia --- p.9 / Chapter 1.1.2.3. --- Classification of leukemia --- p.9 / Chapter 1.1.2.4. --- Epidemiology of leukemia --- p.13 / Chapter 1.1.2.5. --- Conventional treatments for leukemia --- p.15 / Chapter 1.1.2.6. --- Novel approaches to leukemia treatment --- p.18 / Chapter 1.2. --- Statins --- p.22 / Chapter 1.2.1. --- Overview of statins --- p.22 / Chapter 1.2.2. --- Chemical structures of statins --- p.24 / Chapter 1.2.3. --- Pharmacokinetics of statins --- p.26 / Chapter 1.2.4. --- Pleiotropic effects of statins --- p.29 / Chapter 1.2.4.1. --- Anti-inflammatory and immunomodulatory effects of statins --- p.29 / Chapter 1.2.4.2. --- Anti-angiogenic effects of statins --- p.30 / Chapter 1.2.4.3. --- Anti-tumor effects of statins --- p.31 / Chapter 1.3. --- Objectives and scope of the present study --- p.33 / Chapter Chapter 2 --- Materials and Methods / Chapter 2.1. --- Materials --- p.36 / Chapter 2.1.1. --- Animals --- p.36 / Chapter 2.1.2. --- Cell lines --- p.36 / Chapter 2.1.3. --- "Cell culture media, buffers and other reagents" --- p.37 / Chapter 2.1.3.1. --- Cell culture media and reagents --- p.37 / Chapter 2.1.3.2. --- Drugs and chemicals --- p.40 / Chapter 2.1.3.3. --- Reagents and buffers for primary culture --- p.42 / Chapter 2.1.3.4. --- Dye solutions --- p.43 / Chapter 2.1.3.5. --- Reagents for cell proliferation assays --- p.44 / Chapter 2.1.3.6. --- Reagents and buffers for flow cytometry --- p.44 / Chapter 2.1.3.7. --- Reagents for Hoechst staining --- p.45 / Chapter 2.1.3.8. --- Reagents and buffers for DNA isolation --- p.46 / Chapter 2.1.3.9. --- Reagents and buffers for DNA agarose gel electrophoresis --- p.48 / Chapter 2.1.3.10. --- Reagents and buffers for Cell Death ELISA --- p.50 / Chapter 2.1.3.11. --- Reagents and buffers for measuring caspase activity --- p.51 / Chapter 2.1.3.12. --- Reagents and buffers for Western blotting --- p.55 / Chapter 2.1.3.13. --- Reagents for determining nitric oxide production --- p.63 / Chapter 2.2. --- Methods --- p.64 / Chapter 2.2.1. --- Culture of tumor cell lines --- p.64 / Chapter 2.2.2. --- "Isolation, preparation and culture of murine peritoneal macrophages" --- p.64 / Chapter 2.2.3. --- Cell proliferation and cytotoxicity studies --- p.66 / Chapter 2.2.4. --- In vivo tumorigenicity study --- p.68 / Chapter 2.2.5. --- Cell cycle profile and flow cytometric analysis --- p.69 / Chapter 2.2.6. --- Hoechst staining --- p.69 / Chapter 2.2.7. --- DNA fragmentation analysis --- p.70 / Chapter 2.2.8. --- Cell Death ELISA --- p.71 / Chapter 2.2.9. --- Mitochondrial membrane potential analysis --- p.73 / Chapter 2.2.10. --- Measurement of caspase activity --- p.73 / Chapter 2.2.11. --- Protein expression study --- p.75 / Chapter 2.2.12. --- Cell morphological staining --- p.80 / Chapter 2.2.13. --- Cell size and granularity analysis by flow cytometry --- p.81 / Chapter 2.2.14. --- Determination of nitric oxide production by macrophages --- p.81 / Chapter 2.2.15. --- Statistical analysis --- p.82 / Chapter Chapter 3 --- Anti-Proliferative Effect of Statins on Myeloid Leukemia Cells / Chapter 3.1. --- Introduction --- p.84 / Chapter 3.2. --- Results --- p.86 / Chapter 3.2.1. --- Anti-proliferative effect of statins on various murine and human myeloid leukemia cells --- p.86 / Chapter 3.2.2. --- Cytotoxicity of fluvastatin on murine myelomonocytic leukemia WEHI-3B JCS cells --- p.93 / Chapter 3.2.3. --- Cytotoxicity of fluvastatin on primary murine myeloid cells --- p.96 / Chapter 3.2.4. --- Kinetic and reversibility studies on the anti-proliferative effect of fluvastatin on WEHI-3B JCS cells --- p.98 / Chapter 3.2.5. --- Relationship between the anti-proliferative effect of fluvastatin and the cholesterol biosynthesis pathway in WEHI-3B JCS cells --- p.102 / Chapter 3.2.6. --- Effect of fluvastatin on the in vivo tumorigenicity of WEHI-3B JCS cells --- p.106 / Chapter 3.2.7. --- Effect of fluvastatin on the cell cycle profile of WEHI-3B JCS cells --- p.108 / Chapter 3.2.8. --- Effect of fluvastatin on the expression of cell cycle regulatory proteins inWEHI-3B JCS cells --- p.113 / Chapter 3.3. --- Discussion --- p.116 / Chapter Chapter 4 --- Apoptosis- and Differentiation-inducing Effects of Fluvastatin on Murine Myelomonocytic Leukemia WEHI-3B JCS Cells / Chapter 4.1. --- Introduction --- p.124 / Chapter 4.2. --- Results --- p.128 / Chapter 4.2.1. --- Induction of chromatin condensation in WEHI-3B JCS cells by fluvastatin --- p.128 / Chapter 4.2.2. --- Induction of DNA fragmentation in WEHI-3B JCS cells by fluvastatin --- p.130 / Chapter 4.2.3. --- Effect of fluvastatin on the mitochondrial membrane potential in WEHI-3B JCS cells --- p.134 / Chapter 4.2.4. --- Effect of fluvastatin on the caspase activities in WEHI-3B JCS cells --- p.138 / Chapter 4.2.5. --- Effect of fluvastatin on the expression of pro-apoptotic protein AIF in WEHI-3B JCS cells --- p.144 / Chapter 4.2.6. --- Effect of fluvastatin on the morphology of WEHI-3B JCS cells --- p.147 / Chapter 4.2.7. --- Effect of fluvastatin on the cell size and granularity of WEHI-3B JCS cells --- p.149 / Chapter 4.2.8. --- Immunomodulation of murine peritoneal macrophages by fluvastatin --- p.151 / Chapter 4.3. --- Discussion --- p.153 / Chapter Chapter 5 --- Conclusions and Future Perspectives --- p.160 / References --- p.165

Diss. (sammanfattning) Linköping : Linköpings universitet, 2005. / Härtill 4 uppsatser. På omsl. felaktigt " ... daunorobicin ..."

No description available.

Bcr-Abl é a tirosina quinase (TK) responsável por causar a Leucemia Mielóide Crônica (LMC). Os últimos estudos de follow-up mostram que apenas 50% dos pacientes tratados com a segunda geração de inibidores de TK atinge a remissão completa, o que significa que metade desses pacientes necessita de um algo melhor do que está disponível. Wiskott Aldrich Syndrome Protein (WASP) é um gene essencial para o bom desenvolvimento e função das células hematopoiéticas. Ante esse contexto, decidimos investigar se WASP poderia ter algum papel ou relevância na LMC. Em conclusão, Bcr-Abl suprime a expressão WASP por um mecanismo epigenético. A re-expressão de WASP torna as células mais suscetíveis à apoptose em resposta ao Imatinib. Sugerimos que a recuperação da expressão WASP deve ser discutida como estratégia para a terapia da LMC. / Bcr-Abl is the tyrosine kinase (TK) responsible for causing Chronic Myeloid Leukemia (CML). This fusion protein up- and down-regulates several genes and pathways, producing a strong resistance to apoptosis and a blockage of cell maturation in the hematopoietic compartment. The last follow-up studies provided that only 50% of the patients treated with second generation achieve complete remission, what means that one-half of these patients needs something better. Wiskott Aldrich Syndrome Protein (WASP) is an essential gene for the proper development and function of the hematopoietic cells. In the light of this background, we decided to investigate if WASP could have some role or relevance in the CML context. In conclusion, Bcr-Abl suppresses WASP expression by an epigenetic mechanism. The re-expression of WASP makes the CML cells more susceptible to apoptosis and contribute to respond to Imatinib. We suggest that recovery of WASP expression should be discussed as a new and additional strategy for CML therapy.

Tsang Yuen-Man. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 200-218). / Abstracts in English and Chinese. / ACKNOWLEDGEMENTS --- p.i / ABBREVIATIONS --- p.iii / ABSTRACT --- p.vii / CHINESE ABSTRACT --- p.xi / TABLE OF CONTENTS --- p.xiii / Chapter CHAPTER 1: --- GENERAL INTRODUCTION / Chapter 1.1 --- Hematopoiesis --- p.1 / Chapter 1.1.1 --- An Overview on Hematopoiesis --- p.1 / Chapter 1.1.2 --- Role of Cytokines in the Control of Hematopoiesis --- p.4 / Chapter 1.2 --- Leukemia --- p.5 / Chapter 1.2.1 --- Abnormalities in Hematopoietic Cell Development --- p.5 / Chapter 1.2.2 --- Classification of Leukemia --- p.7 / Chapter 1.2.3 --- Etiology and Symptoms of Leukemia --- p.9 / Chapter 1.2.4 --- Therapeutic Strategies for Leukemia --- p.10 / Chapter 1.2.4.1 --- Conventional Therapies --- p.10 / Chapter 1.2.4.2 --- Differentiation Therapy and Induction of Apoptosis in Leukemia --- p.11 / Chapter 1.2.5 --- Regulation of Apoptosis and Cell Cycle Progression --- p.12 / Chapter 1.2.5.1 --- Apoptosis --- p.12 / Chapter 1.2.5.2 --- Cell Cycle --- p.13 / Chapter 1.2.5.3 --- Disregulation of Apoptosis and Cell Cycle Contribute to the Development of Leukemia --- p.14 / Chapter 1.3 --- Licorice --- p.16 / Chapter 1.3.1 --- Chemistry of Licorice --- p.16 / Chapter 1.3.2 --- Pharmacological Activities of Glycyrrhizin and 18-β Glycyrrhetinic Acid --- p.22 / Chapter 1.3.2.1 --- Mineralocorticoid Activity --- p.22 / Chapter 1.3.2.2 --- Anti-inflammatory Effect --- p.23 / Chapter 1.3.2.3 --- Anti-allergic Effect --- p.24 / Chapter 1.3.2.4 --- Enhancement of Immune Response --- p.24 / Chapter 1.3.2.5 --- Anti-hepatotoxic Effects --- p.26 / Chapter 1.3.2.6 --- Anti-viral Activity --- p.27 / Chapter 1.3.2.7 --- Anti-carcinogenic and Anti-tumor Effects --- p.28 / Chapter 1.3.3 --- Other Biological Activities of Licorice --- p.30 / Chapter 1.3.4 --- A 96-kDa Glycyrrhizin-Binding Protein (gb96) --- p.31 / Chapter 1.3.5 --- Evaluation of Health Hazard --- p.32 / Chapter 1.4 --- Aims and Scopes of This Research --- p.34 / Chapter CHAPTER 2: --- MATERIALS AND METHODS / Chapter 2.1 --- Materials --- p.37 / Chapter 2.1.1 --- Animals --- p.37 / Chapter 2.1.2 --- Cell Lines --- p.37 / Chapter 2.1.3 --- "Cell Culture Medium, Buffers and Reagents" --- p.39 / Chapter 2.1.4 --- Recombinant Cytokines --- p.42 / Chapter 2.1.5 --- [methyl-3H] Thymidine (3H-TdR) --- p.43 / Chapter 2.1.6 --- Liquid Scintillation Cocktail --- p.44 / Chapter 2.1.7 --- Reagents and Buffers for Flow Cytometry --- p.44 / Chapter 2.1.8 --- Monoclonal Antibodies --- p.45 / Chapter 2.1.9 --- Reagents for DNA Extraction --- p.47 / Chapter 2.1.10 --- Reagents for Total RNA Isolation --- p.48 / Chapter 2.1.11 --- Reagents and Buffers for RT-PCR Study --- p.49 / Chapter 2.1.12 --- Reagents and Buffers for Gel Electrophoresis --- p.55 / Chapter 2.1.13 --- Reagents and Buffers for Western Blot Analysis --- p.56 / Chapter 2.2 --- Methods --- p.63 / Chapter 2.2.1 --- Culture of the Tumor Cell Lines --- p.63 / Chapter 2.2.2 --- "Isolation, Preparation and Culture of Primary Mouse Cells" --- p.63 / Chapter 2.2.3 --- Determination of Cell Proliferation by [3H]-TdR Incorporation Assay --- p.64 / Chapter 2.2.4 --- Determination of Cell Viability --- p.65 / Chapter 2.2.5 --- Cell Morphology Study --- p.66 / Chapter 2.2.6 --- Apoptosis Study by DNA Fragmentation --- p.66 / Chapter 2.2.7 --- Flow Cytometric Analysis --- p.67 / Chapter 2.2.8 --- Cell Cycle/DNA Content Evaluation --- p.68 / Chapter 2.2.9 --- Gene Expression Study --- p.69 / Chapter 2.2.10 --- Protein Expression Study --- p.72 / Chapter 2.2.11 --- Statistical Analysis --- p.75 / Chapter CHAPTER 3: --- THE ANTI-TUMOR EFFECTS OF GLYCYRRHIZIN AND 18-β GLYCYRRHETINIC ACID ON VARIOUS LEUKEMIC CELL LINES / Chapter 3.1 --- Introduction --- p.76 / Chapter 3.2 --- Results --- p.78 / Chapter 3.2.1 --- The Growth Inhibitory Effects of Glycyrrhizin on Various Leukemic Cell Lines --- p.78 / Chapter 3.2.1.1 --- Differential Anti-proliferative Effects of Glycyrrhizin on Various Leukemic Cell Lines In Vitro --- p.78 / Chapter 3.2.1.2 --- Effects of Glycyrrhizin on the Viability of Various Leukemic Cell Lines and Normal Hematopoietic Cells In Vitro --- p.89 / Chapter 3.2.1.3 --- Induction of DNA Fragmentation in Leukemia Cells by Glycyrrhizin --- p.94 / Chapter 3.2.1.4 --- Effect of Glycyrrhizin on the Cell Cycle Kinetics of HL-60 Cells In Vitro --- p.97 / Chapter 3.2.1.5 --- Effect of Glycyrrhizin on the Cell Cycle Kinetics of JCS Cells In Vitro --- p.100 / Chapter 3.2.1.6 --- Effect of Glycyrrhizin on the In Vivo Tumorigenicity of the Murine Myeloid Leukemia JCS Cells --- p.103 / Chapter 3.2.2 --- The Growth Inhibitory Effects of 18-β Glycyrrhetinic Acid on Various Leukemic Cells Lines --- p.105 / Chapter 3.2.2.1 --- Differential Anti-proliferative Effect of 18-β Glycyrrhetinic Acid on Various Leukemic Cell Lines In Vitro --- p.105 / Chapter 3.2.2.2 --- Effects of 18-β Glycyrrhetinic Acid on the Viability of Various Leukemic Cell Lines and Normal Hematopoietic Cells In Vitro --- p.115 / Chapter 3.2.2.3 --- Induction of DNA Fragmentation in Leukemia Cells by 18-β Glycyrrhetinic Acid --- p.120 / Chapter 3.2.2.4 --- Effect of 18-β Glycyrrhetinic Acid on the Cell Cycle Kinetics of HL-60 Cells In Vitro --- p.123 / Chapter 3.2.2.5 --- Effect of 18-β Glycyrrhetinic Acid on the Cell Cycle Kinetics of JCS Cells In Vitro --- p.126 / Chapter 3.2.2.6 --- Effect of 18-β Glycyrrhetinic acid on the In Vivo Tumorigenicity of the Murine Myeloid Leukemia JCS Cells --- p.129 / Chapter 3.3 --- Discussion --- p.131 / Chapter CHAPTER 4: --- THE DIFFERENTIATION-INDUCING EFFECTS OF GLYCYRRHIZIN AND 18-β GLYCYRRHETINIC ACID ON MURINE MYELOID LEUKEMIA CELLS / Chapter 4.1 --- Introduction --- p.135 / Chapter 4.2 --- Results --- p.138 / Chapter 4.2.1 --- Morphological Changes in Glycyrrhizin or 18-β Glycyrrhetinic Acid-treated JCS Cells --- p.138 / Chapter 4.2.2 --- Surface Antigen Immunophenotyping of Glycyrrhizin or 18-β Glycyrrhetinic Acid-treated JCS Cells --- p.141 / Chapter 4.2.3 --- Endocytic Activity of Glycyrrhizin or 18-β Glycyrrhetinic Acid-treated JCS Cells --- p.155 / Chapter 4.3 --- Discussion --- p.158 / Chapter CHAPTER 5: --- MECHANISTIC STUDIES ON THE ANTI LEUKEMIC ACTIVITIES OF GLYCYRRHIZIN AND 18-P GLYCYRRHETINIC ACID / Chapter 5.1 --- Introduction --- p.161 / Chapter 5.2 --- Results --- p.164 / Chapter 5.2.1 --- Combining Effect of Glycyrrhizin or 18-β Glycyrrhetinic Acid with Hematopoietic Cytokines in Modulating the Proliferation of the Murine Myeloid Leukemia JCS Cells --- p.164 / Chapter 5.2.1.1 --- Combining Effect of Glycyrrhizin and IL-lα on the Proliferation of JCS Cells --- p.164 / Chapter 5.2.1.2 --- Combining Effects of Glycyrrhizin with IFN-γ or TNF-α on the Proliferation of JCS Cells --- p.166 / Chapter 5.2.1.3 --- Combining Effect of 18-β Glycyrrhetinic Acid and IL-lα on the Proliferation of JCS Cells --- p.169 / Chapter 5.2.1.4 --- Combining Effects of 18-β Glycyrrhetinic Acid with IFN-γ or TNF-α on the Proliferation of JCS Cells --- p.169 / Chapter 5.2.2 --- Elucidation of the Molecular Mechanisms of Glycyrrhizin or 18-β Glycyrrhetinic Acid on Leukemic Cell Differentiation and Growth Arrest --- p.173 / Chapter 5.2.2.1 --- Modulatory Effects of Glycyrrhizin and 18-β Glycyrrhetinic Acid on the Expression of Cytokine Genes in the Leukemia JCS Cells --- p.173 / Chapter 5.2.2.2 --- Modulatory Effects of Glycyrrhizin and 18-β Glycyrrhetinic Acid on the Expression of PKC Isoforms in the Leukemia JCS Cells --- p.176 / Chapter 5.2.2.3 --- Modulatory Effects of Glycyrrhizin and 18-β Glycyrrhetinic Acid on the Expression of Growth- regulatory Genes in the Leukemia JCS Cells --- p.180 / Chapter 5.2.2.4 --- Modulatory Effects of 18-β Glycyrrhetinic Acid on the Expression of Apoptosis-related Genes in the Leukemia JCS Cells --- p.183 / Chapter 5.2.2.5 --- Modulatory Effects of 18-β Glycyrrhetinic Acid on the Expression of Growth-regulatory and Apoptosis-related Proteins in JCS Cells --- p.185 / Chapter 5.3 --- Discussion --- p.187 / Chapter CHAPTER 6: --- CONCLUSIONS AND FUTURE PERSPECTIVES --- p.194 / REFERENCES --- p.200

Introdução: O Transplante Alogênico de Célula Tronco Hematopoiética (TCTH alogênico) é um procedimento de alto potencial curativo para a Leucemia Mielóide Aguda (LMA), principalmente pelo efeito “graft versus leukemia” (GVL), que leva a redução do risco de recaída. Atualmente, os pacientes com LMA de risco intermediário são submetidos ao procedimento caso possuam doador aparentado. Pacientes sem doador aparentado disponível são submetidos a tratamento de consolidação com quimioterapia, com maior chance de recaída da doença. Acredita-se que os pacientes submetidos ao TCTH tenham maiores sobrevida global e livre de doença, a despeito das altas taxas de morbimortalidade. A classificação de risco é extremamente importante para escolha terapêutica pós remissão. Assim, a realização da pesquisa de marcadores moleculares, para refinar a estratificação prognóstica, tem importância especial no grupo de risco intermediário, complementando a avaliação citogenética, e auxiliando na decisão terapêutica, sendo cada vez mais necessária, apesar de não disponível em todos os centros. Material e métodos: Foram avaliados os pacientes com LMA de risco intermediário em primeira Remissão Completa (1RC) do Serviço de Hematologia e TCTH do Hospital de Clínicas de Porto Alegre do período de 01 de abril de 1999 a 01 de outubro de 2014, com pelo menos 1 ano de seguimento após o tratamento, através de revisão de prontuários. Os dados foram dispostos no programa Excel e posteriormente exportados para o programa SPSS v. 18.0 para análise estatística. Resultados: Foram avaliados 69 pacientes, sendo 45 pacientes submetidos a consolidação com quimioterapia (“QT”) e 24 submetidos a TCTH Alogênico (“TCTH Alogênico”). A média de idade do grupo “QT” foi de 47,8 anos e do grupo “TCTH Alogênico” foi de 35,5 anos, com diferença estatisticamente significativa (P<0,001). Não houve diferença na distribuição entre o sexo. A mediana de tempo de seguimento do grupo “QT” foi de 1,1 anos (intervalo interquartil de 0,4 a 2,5 ) e no grupo “TCTH Alogênico” foi de 2,7 anos (intervalo interquartil de 0,4 a 5,5), sem diferença estatisticamente significativa na distribuição dos tempos de seguimento entre os grupos (P=0,236). A sobrevida do grupo “QT” em 12 meses foi de 52,3% e no grupo “TCTH Alogênico” foi de 62,5%. Aos 24 meses, a sobrevida do grupo “QT” foi de 31,7% e no grupo “TCTH Alogênico” foi de 58,3% e em 5 anos de 21,1% e 53,8%, respectivamente. O teste do Long-Rank aponta uma diferença estatisticamente significativa nas sobrevidas entre os grupos após 5 anos, com Hazard Ratio (HR) para óbito de 2,2 (IC 95%: 1,1-4,2), P=0,027, porém ao ajustarmos a relação pela idade esta associação perde significância estatística (HR:1,6 IC95%:1 - 1,1; P=0,246) Discussão: Os dados evidenciaram melhor sobrevida no grupo submetido à TCTH alogênico, porém o grupo submetido ao procedimento apresentava média de idade menor. No entanto, apesar da perda da significância estatística, o HR corrigido para idade permanece maior para o grupo sem TCTH, o que pode dever-se ao “n” pequeno da amostra. Identificar quais pacientes terão benefício com TCTH torna-se cada vez mais um desafio. O uso de marcadores moleculares são importantes no refinamento da estratificação de risco do grupo de risco intermediário, podendo auxiliar nessa decisão. Além disso, com o advento da possibilidade de condicionamentos não mieloablativos como alternativa aos pacientes mais velhos e com escore de comorbidades pior e a melhor terapia de suporte, talvez possamos ser menos conservadores na indicação desse procedimento, identificando assim aqueles que poderão obter melhores resultados no tratamento de uma doença tão agressiva e grave. / Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is a high potentially curative procedure to Acute Myeloid Leukemia (AML), mainly by the “graft-versus-leukemia” (GVL) effect, which leads to reduced risk of relapse. Nowadays, intermediate risk AML patients are submitted to this procedure if a matched sibling donor is available. Patients without a sibling donor are submitted to consolidation with chemotherapy, with a greater chance of relapse. It is believed that patients submitted to allo-HSCT have a greater overall survival and disease-free survival, even though it presents high morbidity and mortality rates. Risk stratification is extremely important to post-remission treatment choice. Molecular markers research is especially important in intermediate risk group, complementing cytogenetic evaluation to a better prognostic stratification and, although it is still not available in all health centers, it is more and more necessary. Materials and Methods: We evaluated intermediate risk AML patients in first Complete Remission (CR1) at the Hematology Service and Bone Marrow Transplantation from Hospital de Clínicas de Porto Alegre from April 1st 1999 to October 1st 2014, and which had, at least, a one year follow-up after treatment, by conducting a medical record review. Data was inserted in Microsoft Excel 2010 spreadsheets and after exported to SPSS v. 18.0 to statistical analysis. Results: Among the 69 patients analyzed, 45 were submitted to consolidation with chemotherapy (Intermediate risk AML – non allo-HSCT) and 24 of then submitted to allo-HSCT (Intermediate risk AML – allo-HSCT). The average age of Intermediate risk AML – non allo-HSCT was 47.8 years old and Intermediate risk AML – allo-HSCT was 35.5 years old, with statistically significance difference (P<0,001). There was no difference regard sex of patients. The median follow-up in the Intermediate risk AML – non allo-HSCT was 1.1 years (interquartile rage of 0.4 to 2.5) and in the Intermediate risk AML – allo-HSCT was 2.7 years (interquartile rage of 0.4 to 5.5), with no statistically significance difference in follow-up time distribution between groups (P=0.236). Intermediate risk AML – non allo-HSCT survival in 12 months was 52.3% and in the Intermediate risk AML – allo-HSCT was 62.5%. In 24 months, Intermediate risk AML – non allo-HSCT survival was 31.7% and in Intermediate risk AML – allo HSCT survival was 58.3% and in 5 years it was 21.1% and 53.8% respectively. Long- Rank test indicates a statistically significant difference in survival between groups after 5 years, with hazard ratio (HR) for death of 2.2 (IC95% 1.1 – 4.2), P=0.027, but when we adjust the relation to age, this association loses statistical significance (HR:1.6 95%CI: 1 – 1.1; P=0.246). Discussion: Data showed a better survival rate to the group submitted to allo-HSCT, but the group presented a lower average age. However, despite de loss of statistical significance, Hazard Ratio (HR), adjusted to age remains higher to the non allo-HSCT group. It can be explained by the small number of the sample. Identifying which patients will benefit from allo-HSCT becomes increasingly challenging. The use of molecular markers are important in the refinement of risk stratification in intermediate risk group, assisting in the decision. Moreover, with the advent of the possibility of nonmyeloablative conditioning as an alternative to older patients and with worst rates of comorbidity, and the better supporting therapy, we may be less conservative in indicating this procedure, identifying the patients who may obtain better results during treatment of such aggressive and serious disease.